These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 11045051)

  • 1. [Management of patients with increasing PSA values after curative therapy].
    Fichtner J; Miller K
    Urologe A; 2000 Sep; 39(5):475-82. PubMed ID: 11045051
    [No Abstract]   [Full Text] [Related]  

  • 2. [PSA recurrence following radical prostatectomy and radiotherapy].
    Fichtner J
    Urologe A; 2006 Oct; 45(10):1255-6, 1258-9. PubMed ID: 17006700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.
    Partin AW; Pearson JD; Landis PK; Carter HB; Pound CR; Clemens JQ; Epstein JI; Walsh PC
    Urology; 1994 May; 43(5):649-59. PubMed ID: 7513108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [PSA rise after radical prostatectomy].
    Wirth M; Fröhner M
    Urologe A; 2000 Jan; 39(1):3-8. PubMed ID: 10663189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Management of rising PSA after total prostatectomy].
    Zerbib M
    Ann Urol (Paris); 2007 Oct; 41 Suppl 3():S73-6. PubMed ID: 18297904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent prostate cancer despite undetectable prostate specific antigen.
    Takayama TK; Krieger JN; True LD; Lange PH
    J Urol; 1992 Nov; 148(5):1541-2. PubMed ID: 1279216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate specific antigen only progression of prostate cancer.
    Moul JW
    J Urol; 2000 Jun; 163(6):1632-42. PubMed ID: 10799151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of PSA in diagnosis of prostate cancer and its recurrence].
    Vergho DC; Heine K; Wolff JM
    Pathologe; 2005 Nov; 26(6):473-8. PubMed ID: 16215709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [PSA recurrence after primary curative therapy--local or systemic? When is a second curative therapy still possible?].
    Wirth MP; Engelhardt FM
    Urologe A; 2005 Sep; 44(9):997-1004, 1006-7. PubMed ID: 16133232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant and salvage radiotherapy after radical prostatectomy.
    Höcht S; Wiegel T; Schostak M; Hinkelbein W
    Onkologie; 2002 Jun; 25(3):201-6. PubMed ID: 12119453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSA for outcome prediction and posttreatment evaluation following radiation for prostate cancer: do we know how to use it?
    Kuban DA; El-Mahdi AM; Schellhammer PF
    Semin Radiat Oncol; 1998 Apr; 8(2):72-80. PubMed ID: 9516587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The significance of prostate-specific antigen in after-care of prostate carcinoma].
    Hertle L
    Urologe A; 1998 Mar; 37(2):170-1. PubMed ID: 9563130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An analysis of the time course of postoperative prostate-specific antigen failure in patients with positive surgical margins: implications on the use of adjuvant therapy.
    D'Amico AV; Whittington R; Malkowicz SB; Loughlin K; Schultz D; Schnall M; Tempany CM; Tomaszewski JE; Renshaw A; Wein A
    Urology; 1996 Apr; 47(4):538-47. PubMed ID: 8638365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage radiotherapy for recurrent prostate cancer: the earlier the better.
    Anscher MS
    JAMA; 2004 Mar; 291(11):1380-2. PubMed ID: 15026405
    [No Abstract]   [Full Text] [Related]  

  • 15. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?
    Schriefer P; Steurer S; Huland H; Graefen M
    J Clin Oncol; 2012 Nov; 30(32):e341-4. PubMed ID: 23032622
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience.
    Servoll E; Sæter T; Vlatkovic L; Nesland JM; Waaler G; Axcrona K
    Scand J Urol; 2015 Jun; 49(3):218-23. PubMed ID: 25428750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Modern therapy of prostate cancer].
    Kretschmer A; Stief C; Gratzke C
    MMW Fortschr Med; 2014 Dec; 156(21-22):71-3. PubMed ID: 25608415
    [No Abstract]   [Full Text] [Related]  

  • 19. Radiation therapy after prostatectomy: now or later?
    Schild SE
    Semin Radiat Oncol; 1998 Apr; 8(2):132-9. PubMed ID: 9516594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rate of PSA increase after radiotherapy as an indication of local recurrence or distant metastasis of prostatic carcinoma].
    Landmann C
    Strahlenther Onkol; 1998 Jul; 174(7):383-4. PubMed ID: 9689962
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.